How regenerative medicine M&A performed in the pharmaceutical industry in Q2 2023
In value terms, regenerative medicine-related deal activity remained flat in Q2 2023 compared with the previous quarter and as compared to Q2 2022. Related deal volume increased by 300% in Q2 2023 versus the previous quarter and was 100% higher than in Q2 2022.
The top-ranked financial advisors supporting these M&A deals in Q2 2023 were Evercore; Guggenheim Partners; Houlihan Lokey with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q2 2023 were Goodwin Procter; Cooley; Gibson, Dunn & Crutcher with 2, 1, 1 deals respectively.
For further understanding of GlobalData’s Regenerative Medicine in Medical – Thematic Research, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.
Source link
#regenerative #medicine #performed #pharmaceutical #industry
